Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation

BACKGROUND: Costimulatory blockade provides new therapeutic opportunities for ensuring the long-term survival of kidney grafts. The adoption of the novel immunosuppressant Belatacept has been limited, partly due to concerns regarding higher rates and grades of acute rejection in clinical trials. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hengcheng, Wang, Zijie, Zhang, Jiayi, Gui, Zeping, Han, Zhijian, Tao, Jun, Chen, Hao, Sun, Li, Fei, Shuang, Yang, Haiwei, Tan, Ruoyun, Chandraker, Anil, Gu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959759/
https://www.ncbi.nlm.nih.gov/pubmed/33732243
http://dx.doi.org/10.3389/fimmu.2021.618737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959759/
https://www.ncbi.nlm.nih.gov/pubmed/33732243
http://dx.doi.org/10.3389/fimmu.2021.618737

Ejemplares similares